Podcast appearances and mentions of Johnson Johnson

This episode covers: Cardiology This Week: A concise summary of recent studies ICD Indications in primary prevention Drug treatment of cardiac amyloidosis Mythbusters Host: Rick Grobbee Guests: Carlos Aguiar, Gerhard Hindricks, Marianna Fontana Want to watch that episode? Go to: https://esc365.escardio.org/event/1810   Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.  This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests: Stephan Achenbach, Rick Grobbee, Gerhard Hindricks and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Marianna Fontana has declared to have potential conflicts of interest to report: consultancy for Alnylam, Alexion/Caelum Biosciences, Astrazeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia Therapeutics, Ionis Pharmaceuticals, Cardior, Lexeo Therapeutics, Janssen Pharmaceuticals, Prothena, Pfizer, Novonordisk, Bayer, Mycardium. Research grants from: Alnylam, Bridgbio, Astrazeneca, Pfizer. Share options in LexeoTherapeutics and shares in Mycardium. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Rick Grobbee Guest: Gerhard Hindricks Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1810?r Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests: Stephan Achenbach, Rick Grobbee, Gerhard Hindricks and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This week, we revisit our conversation with Dr. Karyn Gordon (Leadership & Relationship Expert), author of The Three Chairs: How Great Leaders Drive Communication, Performance & Engagement. Karyn is the CEO and co-founder of DK Leadership, a global leadership coaching company whose purpose is developing great leaders at work and home. She has spoken to more than 500,000 people across 17 countries—including Fortune 500 companies, family businesses, entrepreneurs, professional associations, and others.  She is also a media personality & consultant (Good Morning America, Forbes, The New York Times) - and the TV resident Leadership & Relationship Expert for Canada's #1 Talk-Show – Cityline). In 2021, she was nominated for the 29th annual RBC Canadian Women Entrepreneur Award.  Karyn has a Doctorate in Marriage & Family and certifications in Leadership and Emotional Intelligence, Dr. Karyn was invited to collaborate with professors from The Wharton School to develop an EQ training curriculum specifically for family businesses. John Prato, The Consul General of Canada in New York, hosted a reception honoring her work with New York families and organizations. Over the years, she has served as the media spokesperson for Loblaws, Maple Leaf Foods, Johnson & Johnson, Microsoft, eHarmony and UNICEF.  

Carl Quintanilla and Jim Cramer explored what to make of a second day of bank earnings, led by Bank of America, Goldman Sachs and Morgan Stanley. The chip sector's record run also in the spotlight, led by Nvidia trading at all-time highs. The anchors reacted to comments made by Nvidia CEO Jensen Huang in Beijing about doing business in China. The Producer Price Index for June comes in tamer than expected, showing wholesale inflation unchanged month-on-month. Also in focus: ASML drags chip equipment stocks lower, Johnson & Johnson jumps on earnings, President Trump from trade to your 401(K), crypto legislation vote watch. Squawk on the Street Disclaimer

In this episode explore what makes for effective leadership with host Kyle Forrest and Peter Fasolo, former chief human resources officer at Johnson & Johnson. You'll gain insight into the power of systems thinking, board collaboration, aligning your people agenda with enterprise strategy, and more. Tune in now and learn how to lead with impact in today's dynamic HR landscape.

The title is a joke, but it's funny...and who knows, maybe it'll happen. Biggest brand deal ever? lol.Membership Specials https://swolenormousx.com/membershipsDownload The Swolenormous App https://swolenormousx.com/swolenormousappMERCH - https://papaswolio.com/Watch the full episodes here: https://rumble.com/thedailyswoleSubmit A Question⁠ For The Show: https://swolenormousx.com/apsGet On Papa Swolio's Email List: https://swolenormousx.com/emailDownload The 7 Pillars Ebook: https://swolenormousx.com/7-Pillars-EbookTry A Swolega Class From Inside Swolenormous X: https://www.swolenormousx.com/swolegaGet Your Free $10 In Bitcoin: https://www.swanbitcoin.com/papaswolio/   Questions? Email Us: Support@Swolenormous.com

Kiernan Laughlin is the General Manager and co-creator of Deep Indian Kitchen, a growing CPG brand whose mission is to bring a modern, high-quality Indian food experience to consumers worldwide. Kiernan previously held senior brand management roles at large CPG companies like Johnson & Johnson and Unilever, and he spent his early career in marketing, promotions, and partnership leadership at Gorton's Seafood.Highlights from our conversation include:Core business and leadership lessons from Kiernan's career in multi-stage CPG (1:26)Useful skills Kiernan picked up outside of work that have percolated into his leadership style (5:27)Going from a structured corporate environment to leading an emerging brand (8:01)The challenges and opportunities of building a team through rebranding (11:22)Elements that make a successful relationship between CEO and Founder (19:36)Keeping his team aligned and agile as the company evolves (21:48)Hiring for qualities that go beyond the resume (22:49)How Deep connects their mission to action through their foundation (27:08)Advice for the next generation of CPG leaders (30:13)Visit HowIHire.com for transcripts and more on this episode.Follow Roy Notowitz and Noto Group Executive Search on LinkedIn for updates and featured career opportunities.Subscribe to How I Hire:AppleSpotifyAmazon

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZEV865. CME/MOC/AAPA credit will be available until June 30, 2026.Precision Matters in NSCLC: Everything You Need to Know About Biomarker Testing and Targeted Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation, ONC Brothers. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, Johnson & Johnson, Lilly, Nuvalent, Nuvation Bio, and Rigel Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZEV865. CME/MOC/AAPA credit will be available until June 30, 2026.Precision Matters in NSCLC: Everything You Need to Know About Biomarker Testing and Targeted Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation, ONC Brothers. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, Johnson & Johnson, Lilly, Nuvalent, Nuvation Bio, and Rigel Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

We have a powerful conversation about dedication, innovation, and impact in the cystic fibrosis community in this podcast. I'm joined by two incredible guests from MVW Nutritionals: Mike Walters and Jason Vandiver.Mike Walters is a true pioneer in pharmaceutical business and innovation, with nearly four decades of experience. He began his career at Johnson & Johnson, where he spent 14 years in leadership roles across sales, marketing, and management development. In 1996, Mike launched his first company to help organizations navigate product commercialization in the U.S. Since then, his work in the CF space has been nothing short of groundbreaking. He founded and led Source CF, MVW Nutritionals, and CF Global Services, playing a key role in bringing many standard-of-care treatments to market. A Vanderbilt graduate with degrees in Biochemistry and Chemistry, Mike brings both scientific insight and a deep commitment to rare disease care.Joining him is Jason Vandiver, Chief Operating Officer of MVW Nutritionals. A proud Alabama native, Jason earned his degree in Finance from the University of Alabama at Birmingham and spent 16 years in banking before joining MVW during a time of rapid growth. He now helps lead the multimillion-dollar, family-owned company that's become a global leader in nutritional products for patients with CF and non-CF EPI.In this episode, Mike and Jason share their personal stories, the importance of strong partnerships, and the real challenges patients and families are facing—especially as funding landscapes continue to shift. We explore the power of empathy, the strength of community support, and why transparency in nonprofit operations matters now more than ever.It's a conversation about hope, action, and what's ahead as we work together to support those who need us most.   Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/en

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZEV865. CME/MOC/AAPA credit will be available until June 30, 2026.Precision Matters in NSCLC: Everything You Need to Know About Biomarker Testing and Targeted Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation, ONC Brothers. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, Johnson & Johnson, Lilly, Nuvalent, Nuvation Bio, and Rigel Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZEV865. CME/MOC/AAPA credit will be available until June 30, 2026.Precision Matters in NSCLC: Everything You Need to Know About Biomarker Testing and Targeted Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation, ONC Brothers. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, Johnson & Johnson, Lilly, Nuvalent, Nuvation Bio, and Rigel Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZEV865. CME/MOC/AAPA credit will be available until June 30, 2026.Precision Matters in NSCLC: Everything You Need to Know About Biomarker Testing and Targeted Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation, ONC Brothers. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, Johnson & Johnson, Lilly, Nuvalent, Nuvation Bio, and Rigel Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZEV865. CME/MOC/AAPA credit will be available until June 30, 2026.Precision Matters in NSCLC: Everything You Need to Know About Biomarker Testing and Targeted Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation, ONC Brothers. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, Johnson & Johnson, Lilly, Nuvalent, Nuvation Bio, and Rigel Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZEV865. CME/MOC/AAPA credit will be available until June 30, 2026.Precision Matters in NSCLC: Everything You Need to Know About Biomarker Testing and Targeted Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation, ONC Brothers. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, Johnson & Johnson, Lilly, Nuvalent, Nuvation Bio, and Rigel Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZEV865. CME/MOC/AAPA credit will be available until June 30, 2026.Precision Matters in NSCLC: Everything You Need to Know About Biomarker Testing and Targeted Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation, ONC Brothers. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, Johnson & Johnson, Lilly, Nuvalent, Nuvation Bio, and Rigel Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

Host: Perry Elliott Guest: Karim Lekadir Want to watch that episode? Go to: https://esc365.escardio.org/event/1808?r Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests: Stephan Achenbach, Nicolle Kraenkel and Karim Lekadir have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics, AstraZeneca, Forbion. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson."

This episode covers: Cardiology This Week: A concise summary of recent studies Big data in cardiology Measuring lipids: what clinicians need to know Milestones Host: Perry Elliott Guests: Carlos Aguiar, Karim Lekadir, Kostas Koskinas Want to watch that episode? Go to: https://esc365.escardio.org/event/1808 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.  This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests: Stephan Achenbach, Nicolle Kraenkel and Karim Lekadir have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics, AstraZeneca, Forbion. Kostas Koskinas has declared to have potential conflicts of interest to report: speaker fees / honoraria from MSD, Daiichi-Sankyo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Der Pharma- und Konsumgüterhersteller Johnson&Johnson will in Bern-Bümpliz die Impfstoffproduktion einstellen. Nicht nur 300 Arbeitsplätze könnten verloren gehen, sondern auch ein grosses Stück Berner Wirtschaftsgeschichte. Diese reicht bis ins 19. Jahrhundert zurück. Weiter in der Sendung: - Fussball-Euro der Frauen: Was der Grossanlass der Region bringt - und was eben auch nicht. - Dem Kunstmuseum Bern gelingt mit der Kirchner-Ausstellung ein Coup.

The following article of the Health industry is: “Is Mexico Pioneering Next-Generation Surgical Techniques?” by Víctor Matos, Sr. Commercial Director, Johnson & Johnson MedTech Mexico.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/KEE865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2026.Winning GAMBITS Against AML: Guidance on Advances & Medical Breakthroughs with Innovative Targeted Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Myeloid Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas, Daiichi Sankyo, Inc., Johnson & Johnson, Kura Oncology, Inc., Rigel Pharmaceuticals, Inc., Servier Pharmaceuticals LLC, and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/KEE865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2026.Winning GAMBITS Against AML: Guidance on Advances & Medical Breakthroughs with Innovative Targeted Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Myeloid Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas, Daiichi Sankyo, Inc., Johnson & Johnson, Kura Oncology, Inc., Rigel Pharmaceuticals, Inc., Servier Pharmaceuticals LLC, and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/KEE865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2026.Winning GAMBITS Against AML: Guidance on Advances & Medical Breakthroughs with Innovative Targeted Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Myeloid Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas, Daiichi Sankyo, Inc., Johnson & Johnson, Kura Oncology, Inc., Rigel Pharmaceuticals, Inc., Servier Pharmaceuticals LLC, and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/KEE865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2026.Winning GAMBITS Against AML: Guidance on Advances & Medical Breakthroughs with Innovative Targeted Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Myeloid Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas, Daiichi Sankyo, Inc., Johnson & Johnson, Kura Oncology, Inc., Rigel Pharmaceuticals, Inc., Servier Pharmaceuticals LLC, and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/KEE865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2026.Winning GAMBITS Against AML: Guidance on Advances & Medical Breakthroughs with Innovative Targeted Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Myeloid Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas, Daiichi Sankyo, Inc., Johnson & Johnson, Kura Oncology, Inc., Rigel Pharmaceuticals, Inc., Servier Pharmaceuticals LLC, and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/KEE865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2026.Winning GAMBITS Against AML: Guidance on Advances & Medical Breakthroughs with Innovative Targeted Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Myeloid Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas, Daiichi Sankyo, Inc., Johnson & Johnson, Kura Oncology, Inc., Rigel Pharmaceuticals, Inc., Servier Pharmaceuticals LLC, and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TRR865. CME/MOC/AAPA credit will be available until June 30, 2026.Mission Possible in Prostate Cancer: Leveraging Genomics, Modern Therapeutics, and Individualized Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TRR865. CME/MOC/AAPA credit will be available until June 30, 2026.Mission Possible in Prostate Cancer: Leveraging Genomics, Modern Therapeutics, and Individualized Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TRR865. CME/MOC/AAPA credit will be available until June 30, 2026.Mission Possible in Prostate Cancer: Leveraging Genomics, Modern Therapeutics, and Individualized Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TRR865. CME/MOC/AAPA credit will be available until June 30, 2026.Mission Possible in Prostate Cancer: Leveraging Genomics, Modern Therapeutics, and Individualized Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TRR865. CME/MOC/AAPA credit will be available until June 30, 2026.Mission Possible in Prostate Cancer: Leveraging Genomics, Modern Therapeutics, and Individualized Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TRR865. CME/MOC/AAPA credit will be available until June 30, 2026.Mission Possible in Prostate Cancer: Leveraging Genomics, Modern Therapeutics, and Individualized Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This episode covers: Cardiology This Week: A concise summary of recent studies Heart disease risk: Framingham Heart Study insights Sudden death in female athletes Mythbusters: Owning a pet reduces the risk of heart disease Host: Susanna Price Guests: Carlos Aguiar, Sabiha Gati, Vasan Ramachandran Want to watch that episode? Go to: https://esc365.escardio.org/event/1809 Want to watch that extended interview on sudden death in athletes? Go to: https://esc365.escardio.org/event/1809?resource=interview   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. The ESC is not liable for any translated content of this video.The English-language always prevails. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.   Declarations of interests Stephan Achenbach, Sabiha Gati, Nicolle Kraenkel, Susanna Price and Vasan Ramachandran have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Susanna Price Guest: Sabiha Gati Want to watch that extended interview on LDL management? Go to: https://esc365.escardio.org/event/1809?resource=interview Want to watch the full episode? Go to: https://esc365.escardio.org/event/1809   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.  This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails.   Declarations of interests Stephan Achenbach, Sabiha Gati, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Science and technology will bring more change to health care over the next decade than we saw in the past century, says Joaquin Duato, Chairman and CEO, Johnson & Johnson, and a 2025 Distinguished Leadership Award honoree. What drives his confidence, and how is the company creating this future?     Join David K. Young and Duato to discover what he has learned in 36 years at J&J, how the company innovates in science and technology, and how the company supports employees and communities.  This Leadership in Challenging Times discussion is featured as a C-Suite Perspectives podcast and a special CED Policy Watch Webcast. Leadership in Challenging Times features timely and insightful discussions with the outstanding CEOs who are recipients of CED's Distinguished Leadership Awards. Business leader honorees discuss the unprecedented challenges facing the nation and how they are helping chart a path forward for both their companies and communities in which they operate.      (04:08) Leadership Philosophy and Company Culture (06:48) Secrets to Johnson & Johnson's Longevity (09:11) Transforming Health Care with Science and Technology (12:09) Investment Strategies in Health Care Innovation (15:53) Advancing Technology and AI at Johnson & Johnson (18:38) Addressing the Global Health Care Workforce Shortfall (19:41) Ensuring Access to Health Care for Underserved Communities   For more from The Conference Board:  CED Announces Recipients of Its 2025 Distinguished Leadership Awards  CED Distinguished Leadership Awards Celebration 

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/ZAF865. CME/MOC credit will be available until June 15, 2026.Mastering the Evidence and Establishing Best Practices for Making Well-Informed Precision Decisions in EGFR-Mutated NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/ZAF865. CME/MOC credit will be available until June 15, 2026.Mastering the Evidence and Establishing Best Practices for Making Well-Informed Precision Decisions in EGFR-Mutated NSCLC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

Host: Susanna Price Guest: J. Wouter Jukema Want to watch that extended interview on LDL management? Go to: https://esc365.escardio.org/event/1807?resource=interview Want to watch the full episode? Go to: https://esc365.escardio.org/event/1807 Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. J. Wouter Jukema has declared to have potential conflicts of interest to report: J. Wouter Jukema/his department has received research grants from and/or was speaker (CME accredited) meetings sponsored/supported by Abbott, Amarin, Amgen, Athera, Biotronik, Boston Scientific, Dalcor, Daiichi Sankyo, Edwards Lifesciences, GE Healthcare Johnson and Johnson, Lilly, Medtronic, Merck-Schering-Plough, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi Aventis,Shockwave Medical, the Netherlands Heart Foundation, CardioVascular Research the Netherlands (CVON), the Netherlands Heart Institute and the European Community Framework KP7 Programme. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers:  Cardiology this Week: A concise summary of recent studies Coronary sinus reducer: promise in refractory angina Best strategies to reach LDL cholesterol goals in high-risk patients Snapshots Host: Susanna Price Guests: Carlos Aguiar, Rasha Al-Lamee, J. Wouter Jukema, Steffen Petersen Want to watch that episode? Go to: https://esc365.escardio.org/event/1807 Want to watch that extended interview on LDL management? Go to: https://esc365.escardio.org/event/1807?resource=interview Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Rasha Al-Lamee has declared to have potential conflicts of interest to report: speaker's fees for Menarini pharmaceuticals, Abbott, Philips, Medtronic, Servier, Shockwave, Elixir. Advisory board: Janssen Pharmaceuticals, Abbott, Philips, Shockwave, CathWorks, Elixir. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. J. Wouter Jukema has declared to have potential conflicts of interest to report: J. Wouter Jukema/his department has received research grants from and/or was speaker (CME accredited) meetings sponsored/supported by Abbott, Amarin, Amgen, Athera, Biotronik, Boston Scientific, Dalcor, Daiichi Sankyo, Edwards Lifesciences, GE Healthcare Johnson and Johnson, Lilly, Medtronic, Merck-Schering-Plough, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi Aventis, Shockwave Medical, the Netherlands Heart Foundation, CardioVascular Research the Netherlands (CVON), the Netherlands Heart Institute and the European Community Framework KP7 Programme. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

TITLE: Two Emcees Double Down on Event Success (ft. John Di Domenico | Event Emcee | Impersonator | Keynote Speaker)GUEST BIO:Emmy-nominated actor and 5X Best of Las Vegas winner John Di Domenico brings comedy and impressions to corporate events. Featured on Conan, Kimmel, and Howard Stern, he's collaborated with Fortune 500 companies like AT&T, Johnson & Johnson, and American Express as a professional emcee, delivering memorable experiences through custom content.OPENING QUOTE:Because the thing that an emcee does best, you and I do, that people can't see. If we do it right, it's seamless. It's that we keep the meeting moving, we keep the audience engaged, we read the audience. Do they need a serious moment here? Do they need to physically stand up? What do they need to keep that high level of engagement?SUMMARY:Scott Bloom and John Di Domenico, both experienced MCs and performers, reflect on their careers and long friendship. They share how their journeys in stand-up comedy led them into the world of corporate events. Both started their entertainment careers doing stand-up from a young age, but realized the corporate event world allowed them to use their skills in more creative and collaborative ways.John shares the path he took from performing in clubs and working as a copywriter to becoming a sought-after corporate entertainer, impersonator, and MC. He talks about the importance of deep customization—learning about the company, its culture, and the people in the audience—to deliver performances that truly resonate. Scott echoes this, highlighting how being able to read the room and keep audiences engaged is what sets professional MCs apart from internal company hosts.John details his unique process for preparing for events, from extensive research into company backgrounds to speech warmups (a legacy of overcoming childhood speech impediments). He also touches on his journey from doing full-character impersonations (complete with wigs and prosthetics) to performing as himself while using his array of voices and impressions for added flavor. Both hosts note that today's audiences for business events are more sophisticated and expect a "show," not just a meeting.The episode finishes with a fun rapid-fire Q&A where John reveals his favorite character (Austin Powers), his go-to karaoke song, and his hidden talents. The conversation overall is engaging, light-hearted, and packed with wisdom for the new event professional to the seasoned professional.HIRE THEM TO HOST OR SPEAK:Follow John Di Domenico: thejohnnydshow.com/Follow Scott Bloom: eSpeakers BioFollow eSpeakers: eSpeakers MarketplaceABOUT NO MORE BAD EVENTS:Brought to you by eSpeakers and hosted by professional emcee, host, and keynote speaker Scott Bloom, No More Bad Events is where you'll hear from some of the top names in the event and speaking industry about what goes on behind the scenes at the world's most perfectly executed conferences, meetings, and more. Get ready to learn the secrets and strategies to help anyone in the event industry reach their goal of putting on nothing less than world-class events.Learn more at nomorebadevents.com.ABOUT THE HOST:A veteran comedian and television personality who has built a reputation as the go-to choice for business humor, Scott has hosted hundreds of events over two decades for big and small organizations alike. Scott has also hosted his own weekly VH1 series and recently co-hosted a national simulcast of the Grammy Awards from the Palace Theater.As the son of a successful salesman, he was exposed to the principles of building a business at an early age. As a comedian, Scott cut his teeth at renowned improv and comedy clubs. As a self-taught student of psychology, he's explored what makes people tick and has written a book (albeit a farce) on how to get through life. He's uniquely positioned to deliver significant notes on connecting people and making business seriously funny. And who doesn't like to laugh?Learn more about Scott: scottbloomconnects.comPRODUCED BY eSpeakers:When the perfect speaker is in front of the right audience, a kind of magic happens where organizations and individuals improve in substantial, long-term ways. eSpeakers exists to make this happen more often.eSpeakers is where the speaking industry does business on the web. Speakers, speaker managers, associations, and bureaus use our tools to organize, promote, and grow successful businesses. Event organizers think of eSpeakers first when they want to hire speakers for their meetings or events.The eSpeakers Marketplace technology lets us and our partner directories help meeting professionals worldwide connect directly with speakers for great engagements.Thousands of successful speakers, trainers, and coaches use eSpeakers to build their businesses and manage their calendars. Thousands of event organizers use our directories every day to find and hire speakers. Our tools are built for speakers, by speakers, to do things that only purpose-built systems can.Learn more at eSpeakers.com.SHOW CREDITS:● Scott Bloom: Host | scottbloomconnects.com● Joe Heaps: eSpeakers | jheaps@eSpeakers.com

En este episodio de re:INVÉNTATE, llevamos el storytelling de liderazgo de la teoría a la **aplicación pura y práctica** con 10 situaciones reales que vives cada semana.¿Te cuesta que aprueben tus propuestas? ¿No sabes cómo dar feedback sin desmotivar? ¿Tus celebraciones suenan vacías? La diferencia entre el éxito y el fracaso en estas situaciones **no son los datos que presentas**, sino las historias que cuentas.Pero no hablamos de inspiración genérica. Hablamos de **scripts exactos**, palabras probadas, estructuras que funcionan en el mundo real corporativo.En este episodio aprenderás:✅ Cómo pedir presupuesto y conseguir el SÍ (con el método que usa Warren Buffett).✅ Los scripts exactos para dar feedback difícil construyendo, no destruyendo.✅ Cómo inspirar en crisis siguiendo el playbook de Johnson & Johnson con Tylenol.✅ Las palabras precisas para kick-offs de proyecto, pedir esfuerzo extra, rechazar peticiones y 5 situaciones más. Si quieres dejar de improvisar en momentos críticos de liderazgo y tener las palabras exactas que generan resultados, este episodio es para ti.Déjanos ⭐️⭐️⭐️⭐️⭐️ para ayudarnos a llegar a más personas con este contenido transformador: *re:INVÉNTATE* en Spotify y Apple Podcasts.¿Tienes preguntas o quieres compartir tus progresos en el desarrollo de este PowerSkill? Etiquétame en Instagram (@librosparaemprendedores) en una stories o deja tus comentarios y opiniones sobre este episodio.✨ ¡Hoy comienza tu re:Invención!

CHROs, your role has never been more vital or more complex. AI, shifting politics, hybrid work, and evolving employee expectations, have taken the front seat in today's world of work. The future says you're no longer just managing HR, you're redefining the workplace itself. That's exactly why I launched Future of Work Leaders, a supportive global community built specifically for CHROs who are ready to move beyond traditional HR and are committed to building future-ready organizations.  In this episode, I share highlights from our very first 2025 gathering, where CHROs from some of the world's most respected brands came together to discuss the real challenges and opportunities shaping the future of work. I'm taking you behind the scenes of our inaugural Future of Work Leaders CHRO event, hosted at the Neiman Marcus Innovation Hub in Dallas. We brought together 40 CHROs from organizations like Johnson & Johnson, Northrop Grumman, Tractor Supply, Amway, and others to have deep, honest conversations about what's really driving change today. Topics like the evolving role of DEI, AI integration, hybrid work models, culture transformation, and even the political climate's impact on work. ________________ Start your day with the world's top leaders by joining thousands of others at Great Leadership on Substack. Just enter your email: ⁠⁠https://greatleadership.substack.com/

Debbie Reynolds, Chief Data Privacy Officer and host of “The Data Diva Talks Privacy” podcast, discusses the challenges parents face in protecting their children online, and simple habits users can adopt to take back control of their privacy. She also discusses the growing recognition among companies that excessive data collection poses significant risks. Key Takeaways:  How consumer expectations for data are privacy changing The asymmetrical relationship between consumers and companies regarding data privacy How companies can scale a human‑centric approach to privacy The importance of decentralization in future data management Guest Bio: Debbie Reynolds—aka “The Data Diva”—is a globally recognized technologist, thought leader, and advisor in data privacy and emerging technology. With over 20 years of experience, she has delivered keynote talks for major organizations like Coca-Cola, Johnson & Johnson, PayPal, TikTok, and Uber. Her insights have been featured in leading media outlets, including The New York Times, Forbes, Bloomberg, and Wired. Debbie hosts the #1 global award-winning podcast, “The Data Diva Talks Privacy,” which reaches listeners in over 120 countries. Identity Review has named her one of the Global Top Eight Privacy Experts, and the European Risk Policy Institute has named her a Top 30 CyberRisk Communicator. She also chairs the IEEE Cyber Security Committee for the Next Generation Connectivity Systems Privacy Labeling Project. ---------------------------------------------------------------------------------------- About this Show: The Brave Technologist is here to shed light on the opportunities and challenges of emerging tech. To make it digestible, less scary, and more approachable for all! Join us as we embark on a mission to demystify artificial intelligence, challenge the status quo, and empower everyday people to embrace the digital revolution. Whether you're a tech enthusiast, a curious mind, or an industry professional, this podcast invites you to join the conversation and explore the future of AI together. The Brave Technologist Podcast is hosted by Luke Mulks, VP Business Operations at Brave Software—makers of the privacy-respecting Brave browser and Search engine, and now powering AI everywhere with the Brave Search API. Music by: Ari Dvorin Produced by: Sam Laliberte

This episode of PedsCases will give you an approach to congenital hemangiomas. By the end of this podcast, listeners will be able to 1) define hemangiomas and congenital hemangiomas, 2) explain the genetics and environmental factors associated with congenital hemangiomas, 3) describe the pathogenesis of congenital hemangiomas, 4) classify congenital hemangiomas, and 5) discuss the diagnosis, differential diagnosis, and management strategies for congenital hemangiomas. Today's episode was created by Emilie Wang, a medical student at the University of British Columbia, in collaboration with Dr. Joseph Lam, a pediatric dermatologist at BC Children's Hospital. An author of this podcast has financial support and has received speaker bursaries from Johnson & Johnson, Pierre-Fabre, Pfizer, Valeant, Sanofi Genzyme, Incyte, La Roche Posay Canada, Beiersdorf Canada and serves on advisory committees for Johnson & Johnson, Pierre-Fabre, Pfizer, Valeant, Sanofi Genzyme. They also serve as Associate Editor of Pediatric Dermatology Journal, and have been contributors to UpToDate, Medscape, BMJ Updates, and Eczema Society of Canada.  

John Green returns to the show to talk about tuberculosis — a disease that kills more than a million people a year. Steve has an idea for a new way to get treatment to those in need. SOURCES: John Green, best-selling author and YouTube creator. RESOURCES: Everything Is Tuberculosis: The History and Persistence of Our Deadliest Infection, by John Green (2025)."The Deadliest Infectious Disease Isn't a Science Problem. It's a Money Problem," by John Green (The Washington Post, 2024)."The Deadliest Infectious Disease of All Time," by John Green (Crash Course, 2024)."Barely Contained Rage: An Open Letter to Johnson & Johnson," by John Green (Vlogbrothers, 2023)."Designing Advance Market Commitments for New Vaccines," by Michael Kremer, Jonathan D. Levin, and Christopher M. Snyder (NBER, 2020)."Are CEOs Rewarded for Luck? The Ones Without Principals Are," by Marianne Bertrand and Sendhil Mullainathan (The Quarterly Journal of Economics, 2001)."A Further Communication on a Remedy for Tuberculosis," by Robert Koch (The Indian Medical Gazette, 1891). EXTRAS: "His Brilliant Videos Get Millions of Views. Why Don't They Make Money?" by People I (Mostly) Admire (2025)."Sendhil Mullainathan Thinks Messing Around Is the Best Use of Your Time (Update)," by People I (Mostly) Admire (2024)."John Green's Reluctant Rocket Ship Ride (Update)" by People I (Mostly) Admire (2024)."Rajiv Shah Never Wastes a Crisis," by People I (Mostly) Admire (2024)."'There's So Many Problems — Which Ones Can I Make a Difference On?'" by People I (Mostly) Admire (2022).The Anthropocene Reviewed: Essays on a Human-Centered Planet, by John Green (2021).The Anthropocene Reviewed (podcast).Nerdfighteria.TBFighters.

Scott Wapner and the Investment Committee debate the rebound in stocks as the S&P 500 heads for its longest winning streak in 20 years. The experts detail their latest portfolio moves. CNBC Senior Markets Commentator Michael Santoli joins from Omaha with a special Midday Word ahead of Berkshire Hathaway's annual shareholder meeting. Calls of the Day include AutoZone, Roblox, Eli Lilly, Johnson & Johnson, and Quanta Services. NBC Sports host Mike Tirico is live in Churchill Downs ahead of the 151st Kentucky Derby. The Setup is on Ferrari, Zoetis, Elanco Animal Health.Investment Committee Disclosures

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: A new Austrailian study aims to prevent type 1, the new twiist pump will integrate with Eversnse CGM as well as Libre, diabetes deaths are down in the US, Dexcom U is looking for college athletes, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX A world-first human trial of a drug designed to treat the underlying cause of type 1 diabetes has begun in Australia. University of Queensland researcher Ranjeny Thomas said the experimental drug — dubbed ASITI-201 — was designed to retrain the immune system so it no longer attacks the insulin-producing pancreatic cells, known as beta cells. The drug, given as an injection under the skin, combines fragments of a protein found in the beta cells of people with type 1 diabetes and vitamin D to calm the immune response. She said if effective, the drug would initially be given to patients with type 1 diabetes as soon as possible after diagnosis to preserve remaining pancreatic cells and reduce the amount of insulin needed. But eventually, if screening programs can be developed to pick up people at risk of developing type 1 diabetes, it may be possible to "prevent the progression of the disease altogether". The first in-human trial of 36 participants will test the safety of the drug, but blood tests will also determine the impact of the therapy on a patient's immune system and glucose tolerance. https://www.abc.net.au/news/2025-04-29/type-1-diabetes-drug-trial-auto-immune-disease-science/105223022 XX   Diabetes deaths in the U.S. have fallen to some of the lowest rates in years, according to new preliminary figures published by the Centers for Disease Control and Prevention, reversing a surge in mortality that was seen during the COVID-19 pandemic.   There were 26.4 deaths per 100,000 people from diabetes, according to early death certificate data for the third quarter of 2024 published this month by the CDC's National Center for Health Statistics.   Death rates from diabetes peaked in 2021, according to CDC figures, at 31.1 deaths per 100,000 people for that year. Diabetes was the eighth leading cause of death in 2021. The CDC says the link between COVID-19 and diabetes may be to blame for that increase.   "Data show an increase in mortality rates for all people during the COVID-19 pandemic, and research shows that people with underlying conditions, including diabetes, are more likely to become very sick from COVID-19 and have a higher risk of hospitalization and death," Christopher Holliday, head of the CDC's Division of Diabetes Translation, told CBS News in a statement.   Holliday added that research shows the pandemic may also have made it harder for Americans to properly manage the disease, ranging from interruptions to physical activity to disruptions to routine medical care diagnosing and treating the disease.   https://www.cbsnews.com/news/diabetes-deaths-lowest-levels-years-early-cdc-figures/ XX Big news for the Eversense CGM – they have their first pump partner. Sequel Med Tech says the twist pump will integrate with Senseonics Eversense 365 continuous glucose monitor (CGM). This collaboration would make twiist the first AID system compatible with Eversense 365, the world's first and only one-year CGM. Sequel and Senseonics say they have already started their work to integrate the latest-generation, 365-day implantable sensor with twiist. They expect to make the integrated offering available in the third quarter of this year. This marks the second CGM integration for Sequel, which partnered with Abbott and its FreeStyle Libre platform earlier this year. This week we also got a peek at the packaging and delivery of the twist as the first people posted about wearing it. We'll follow up and learn more about this newest insulin pump in the us. Senseonics, meanwhile, brought the first year-long CGM to market last year, launching Eversense 365 with its global distribution partner, Ascensia Diabetes Care, in October 2024. The system also received clearance as an integrated CGM (iCGM) system, meaning it can work with compatible medical devices. Those include insulin pumps as part of automated insulin delivery systems. https://www.drugdeliverybusiness.com/sequel-senseonics-integrate-cgm-insulin-pump/ XX Medtronic has announced the U.S. Food and Drug Administration (FDA) approval for the Simplera Sync sensor for use with the MiniMed 780G system. With this approval, the MiniMed 780G system now offers more flexibility for users of the company's most advanced insulin delivery system featuring Meal Detection technology with both the Guardian 4 sensor and Simplera Sync sensor.   The Simplera Sync is a disposable, all-in-one sensor that requires no fingersticks with SmartGuard or overtape and features a simple, two-step insertion process. It is the company's newest addition to its CGM portfolio, which expands options and provides greater flexibility for users.   The MiniMed 780G system's adaptive algorithm automatically anticipates, adjusts, and corrects glucose levels every 5 minutes, 24/7 – working around the clock so users can focus on what matters. It's the only system featuring Meal Detection technology, which detects rising sugar levels and delivers more insulin as needed to help users keep glucose levels in range more often – even when users occasionally forget to dose insulin for snacks or meals or underestimate their carbs.   The system uses a “treat to target” approach and flexible glucose targets as low as 100 mg/dL, which, combined with its adaptive algorithm allows it to more closely mirror the glucose levels of someone not living with diabetes.   Real-world data of the system shows global users consistently achieve time in range above international targets of 70% when using optimal settings (active insulin time of two hours and 100 mg/dL target glucose). It is also the only system that works with the world's only infusion set that lasts up to 7 days so that users only have to change their infusion set once per week and can experience 96% fewer injections compared to multiple daily injections.   “We're committed to driving innovation that makes life easier for those living with diabetes so they can forget about their diabetes as much as possible throughout the day,” said Que Dallara, EVP and president of Medtronic Diabetes. “Our MiniMed 780G system delivers advanced diabetes technology for so many around the world, and we're excited to continue evolving this experience with expanded CGM options —including our Simplera Sync sensor, which we look forward to bringing to people living with diabetes in the U.S.”   A limited launch of the Simplera Sync sensor will begin in the U.S. in the fall of 2025. Today, the MiniMed 780G system can be used with the Guardian 4 sensor.   Like this:https://med-techinsights.com/2025/04/29/simplera-sync-sensor-for-minimed-780g-now-fda-approved/ XX Front office changes at Insulet.. The former head of Johnson & Johnson's worldwide medtech business, Ashley McEvoy will take over as president and CEO from Jim Hollingshead, who has led Insulet since 2022. In its announcement of the leadership change, Insulet said that Hollingshead and the company mutually agreed to part ways, effective immediately. McEvoy served as worldwide medtech chairman at J&J from 2018 until her departure in late 2023, the culmination of nearly 30 years at the company and several executive roles—including president of its Ethicon division and group chairman of vision and diabetes care. Since then, she has also served as a board member at Procter & Gamble. https://www.fiercebiotech.com/medtech/insulet-taps-former-jj-medtech-head-ashley-mcevoy-be-ceo XX New free mobile game launched this week to make type 1 diabetes onboarding faster easier and less overwhelming. It's called Level One.. created by Level Ex (Powered by Relevate Health), the studio behind award-winning medical games for medical professionals. Level Ex CEO Sam Glassenberg created the game after a – quote  - brutal onboarding experience when his daughter was diagnosed five years ago He says  It took a year to understand how to manage this disease. So we fixed it. We built a game that can train your brain to do it in a matter of hours." The game is launching in partnership with leading diabetes organizations Beyond Type 1 and Breakthrough T1D Play, who are integrating Level One into their outreach and educational campaigns to support newly diagnosed families worldwide. Download Level One on the App Store: https://apps.apple.com/us/app/level-one-a-diabetes-game/id6739605694 Learn more: https://playlevelone.com   https://www.prnewswire.com/news-releases/level-ex-launches-level-one-a-free-mobile-game-to-redefine-type-1-diabetes-onboarding-302440929.html XX   Collagen is widely recognized for its role in maintaining healthy skin, but its importance extends far beyond that. As the most abundant protein in the human body, collagen provides essential structure and support to nearly all tissues and organs.   Now, researchers at Carnegie Mellon's Feinberg Lab have made a major breakthrough using their novel Freeform Reversible Embedding of Suspended Hydrogels (FRESH) 3D bioprinting technique. This method enables the precise printing of soft, living cells and tissues. Leveraging this technology, the team successfully created the first-ever microphysiologic system, also known as a tissue model, constructed entirely from collagen. This advancement opens new possibilities for studying disease and engineering tissue therapies, including potential treatments for conditions like Type 1 diabetes.   Traditionally, small-scale models of human tissue, referred to as microfluidics, organ-on-chip devices, or microphysiologic systems, have been fabricated using synthetic materials such as silicone rubber or plastics. These materials were necessary due to limitations in earlier manufacturing techniques. However, because they are not biologically native, they fail to fully replicate natural tissue environments, restricting their effectiveness in biomedical research and therapeutic development.   “Now, we can build microfluidic systems in the Petri dish entirely out of collagen, cells, and other proteins, with unprecedented structural resolution and fidelity,” explained Adam Feinberg, a professor of biomedical engineering and materials science & engineering at Carnegie Mellon University. “Most importantly, these models are fully biologic, which means cells function better.”   Building Complex Tissues with FRESH Bioprinting In new research published in Science Advances, the group demonstrates the use of this FRESH bioprinting advancement, building more complex vascularized tissues out of fully biologic materials, to create a pancreatic-like tissue that could potentially be used in the future to treat Type 1 diabetes. This advancement in FRESH bioprinting builds on the team's earlier work published in Science, by improving the resolution and quality to create fluidic channels that are like blood vessels down to about 100-micron diameter.   “There were several key technical developments to the FRESH printing technology that enabled this work,” described Daniel Shiwarski, assistant professor of bioengineering at the University of Pittsburgh and prior postdoctoral fellow in the Feinberg lab. “By implementing a single-step bioprinting fabrication process, we manufactured collagen-based perfusable CHIPS in a wide range of designs that exceed the resolution and printed fidelity of any other known bioprinting approach to date. Further, when combined with multi-material 3D bioprinting of ECM proteins, growth factors, and cell-laden bioinks and integration into a custom bioreactor platform, we were able to create a centimeter-scale pancreatic-like tissue construct capable of producing glucose-stimulated insulin release exceeding current organoid based approaches.” https://scitechdaily.com/scientists-bioprint-living-tissues-that-could-revolutionize-diabetes-treatment/ XX Another study showing the blood sugar benefit of walking after a meal. Skeletal muscle plays a central role in glucose uptake. Exercise stimulates glucose transport into muscle cells through insulin-independent pathways, notably through the action of glucose transporter type 4 (GLUT-4), which is responsible for transporting glucose from blood to skeletal muscles.4 This means that even without a robust insulin response, physical activity can facilitate glucose clearance from the bloodstream. These effects also occur without requiring high-intensity exercise, making postprandial walking accessible to a broad range of individuals, including those with limited exercise tolerance. multiple studies show that starting activity within 30 minutes after a meal is optimal. https://www.news-medical.net/health/Walking-After-Meals-Small-Habit-Big-Metabolic-Gains.aspx XX Dexcom brings back Dexcom U for a 4th years. This is a name, image and license program for college athletes with diabetes and includes a nationwide open call for passionate and inspiring college athletes to join its roster. Now through May 23, athletes, coaches, friends and family members can nominate candidates through an online submission. Those selected, along with the eight returning athletes from last year, will be invited to attend the Dexcom U Signing Day Camp this summer, hosted by Dexcom Warrior and Baltimore Ravens tight end Mark Andrews. https://www.hmenews.com/article/dexcom-u-returns-for-fourth-season

The Rich Zeoli Show- Full Show (04/30/2025): 3:05pm- Last night, President Donald Trump celebrated the first 100 Days of his second term in office with a rally in Michigan—highlighting his successes and calling out Democrats who are already seeking to impeach him. Tonight, former Vice President Kamala Harris is expected to deliver her own address—her first major speech since losing the 2024 presidential election. According to reports, she is expected to “call out” President Trump and his administration. 3:30pm- On Monday, Rich, Matt, and Rich's son Patrick visited the White House to celebrate the first 100 days of President Trump's second term in office—as well as the Super Bowl Champion Philadelphia Eagles. While the visit was enjoyable, why didn't Matt stop for food on the way home??? 3:40pm- On Tuesday night, President Donald Trump sat down for an interview with Terry Moran of ABC News. During the conversation, Trump defended his decision to revoke Joe Biden's security clearances. He also said he considers securing the border his greatest accomplishment thus far. 3:50pm- World War II Bomb in Cape May? According to a report from Fox 29, an unexploded World War II ordinance was discovered during low tide earlier this week—forcing a bomb squad to deactivate the device. 4:05pm- During Wednesday's cabinet meeting, Treasury Secretary Scott Bessent said the rare earth mineral deal with Ukraine “is ready to sign”—and although Ukraine recently made “some last-minute changes” it could be agreed upon as soon as “this afternoon.” Meanwhile, Secretary of State Marco Rubia reacted to Kilmar Abrego Garcia's deportation to El Salvador. He noted that “the conduct of our foreign policy belongs to the President of the United States and the Executive Branch—not some judge.” 4:40pm- Health and Human Services Secretary Robert Kennedy Jr. discussed his efforts to “make America healthy again” during Wednesday's cabinet meeting with President Donald Trump. Sec. Kennedy specifically touted his department's recently announced “ban on nine petroleum-based synthetic food dyes.” 5:00pm- On Wednesday, President Donald Trump held a press conference announcing financial investments in America from companies like Amazon, IBM, Nvidia, Johnson & Johnson, and Eli Lilly & Company. In total, the Trump Administration estimates that the investments in “America's future” amount to over $5 trillion in his first 100 days in office—with the creation of “more than 451,000 new jobs.” 5:30pm- “Shark Tank” star Kevin O'Leary hilariously explained that socialist Rep. Alexandria Ocasio Cortez is really a capitalist—pointing out her “Tax the Rich” t-shirts which she makes an “82% margin on.” 6:05pm- Daniel Turner—Founder and Executive Director of Power the Future—joins The Rich Zeoli Show to discuss his latest op-ed for The New York Post, “How Trump turned around a Biden energy policy based on hand waves and lies.” You can read the full article here: https://nypost.com/2025/04/28/opinion/how-trump-turned-around-a-biden-energy-policy-based-on-hand-waves-and-lies/. 6:30pm- During Wednesday's cabinet meeting, President Donald Trump thanked Elon Musk for his work at DOGE—as Musk begins to transition back to his work in the private sector. Plus, Governor Gavin Newsom claims he invented DOGE six years ago…but that California did it better than the Trump Administration. What the heck is he talking about!?

The Rich Zeoli Show- Hour 3: 5:00pm- On Wednesday, President Donald Trump held a press conference announcing financial investments in America from companies like Amazon, IBM, Nvidia, Johnson & Johnson, and Eli Lilly & Company. In total, the Trump Administration estimates that the investments in “America's future” amount to over $5 trillion in his first 100 days in office—with the creation of “more than 451,000 new jobs.” 5:30pm- “Shark Tank” star Kevin O'Leary hilariously explained that socialist Rep. Alexandria Ocasio Cortez is really a capitalist—pointing out her “Tax the Rich” t-shirts which she makes an “82% margin on.”

Johnson & Johnson recently lost a bid to settle lawsuits that claimed its talc powder products, including baby powder, caused cancer. Author Gardiner Harris says the company's defense "is beginning to crumble." His book is No More Tears. Also, John Powers reviews the new Apple TV+ series Your Friends & Neighbors, starring Jon Hamm.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy